0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-2

Angiopoietin-2

Brief Information

Name:Angiopoietin-2
Target Synonym:ANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:NDA/BLA

Product ListCompare or Buy

Part of Bioactivity data

AN2-M52H3-ELISA
Mouse Angiopoietin-2, His TagMouse Angiopoietin-2, His Tag (Cat. No. AN2-M52H3) ELISA bioactivity

Immobilized Human TIE2, Fc Tag (Cat. No. TI2-H5255) at 2 μg/mL (100 μL/well) can bind Mouse Angiopoietin-2, His Tag (Cat. No. AN2-M52H3) with a linear range of 2-39 ng/mL (QC tested).

MBS-K035-ELISA
Human ANGPT2-coupled Magnetic BeadsHuman ANGPT2-coupled Magnetic Beads (Cat. No. MBS-K035) ELISA bioactivity

Immobilized 47μg ANGPT2 protein/1mg beads can bind Human TIE2 Protein, Fc Tag (Cat. No. TI2-H5255) with an EC50 of 3.228 μg/mL (QC tested).

Synonym Name

ANGPT2,AGPT2,ANG2,Angiopoietin-2

Background

Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MEDI-3617 ANG-2-mAb; MEDI-3617; Anti-ANG-2-mAb Phase 1 Clinical Medimmune Ovarian Neoplasms; Melanoma Details
LY-3127804 LY-3127804 Phase 2 Clinical Eli Lilly And Company Pneumonia; Neoplasms; Coronavirus Disease 2019 (COVID-19) Details
Aflibercept/Nesvacumab REGN 910-3 Phase 2 Clinical Regeneron Pharmaceuticals Inc Diabetic macular oedema; Macular Degeneration Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code) Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms; Colorectal Neoplasms Details
RO-7250284 RO-7250284 Phase 1 Clinical F. Hoffmann-La Roche Ltd Macular Degeneration Details
Trebananib AMG-386; 20060439 Phase 2 Clinical Amgen Inc, Takeda Pharmaceutical Co Ltd Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Rectal Neoplasms; Kidney Diseases; Colonic Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms Details
AMG-780 AMG-780 Phase 1 Clinical Amgen Inc Solid tumours; Neoplasms Details
Y-400 Y-400 Clinical Wuhan Yzy Biopharma Details
BI-836880 BI-836880 Phase 2 Clinical Ablynx Wet Macular Degeneration; Carcinoma, Squamous Cell; Macular Degeneration; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop